mRCAT-III NCT06507371
ForpMMR/MSS cT3-4N0/+M0 rectal adenoCa, ≤10cm from anal verge, no lateral node
61.0% vs 28.6%
P<0.0001, blinded independent central review
TL;DRpCR 61.0% vs 28.6% (P<0.0001) when elective nodal RT was omitted and tislelizumab added in pMMR/MSS LARC.
The RT variable here is target volume, not dose: both arms got 5Gy x 5d, and the experimental target was tumor bed alone with tumor-draining nodes deliberately spared. That inverts the usual de-escalation logic (smaller field proposed to IMPROVE efficacy by preserving nodal immunity), but tislelizumab moves with it, so the pCR gain cannot be assigned to the field change.
In pMMR/MSS cT3-4 rectal cancer ≤10cm from the verge with no positive lateral node, this raises the question of elective nodal omission with PD-1 blockade but does not yet support dropping nodal coverage outside a trial, and says nothing about dMMR/MSI-H disease.
The only RT variable is target volume: 5Gy x 5d in both arms, tumor bed alone versus conventional fields including the tumor-draining nodes. Elective nodal omission is being proposed to improve efficacy rather than reduce toxicity, but with no recurrence data reported, the coverage decision stays unchanged outside a trial.
Tislelizumab was added to an unchanged CAPOX backbone in a pMMR/MSS population, where checkpoint blockade has generally underperformed. The 61.0% vs 28.6% pCR is the sequencing signal, though the concurrent field reduction means the drug's independent contribution is not isolated.
All patients proceeded to TME, so the higher pCR (61.0% vs 28.6%) and MPR (77.9% vs 50.6%) bear on the depth of response at resection and, via the unreported organ-preservation secondary, on which patients might avoid it. Nodal yield and recurrence after unirradiated draining nodes are not reported.
| Endpoint (ITT) | Experimental (N=77) | Control (N=77) | P |
|---|---|---|---|
| pCR rate | 61.0 (47/77) | 28.6 (22/77) | <0.001 |
| MPR rate | 77.9 (60/77) | 50.6 (39/77) | <0.001 |
+1 more figure
10 details 5 trials watching
Multicenter, open-label, randomized phase 3 across 17 hospitals in China (NCT06507371). 1:1 allocation, n=77 per arm, stratified by clinical N stage (cN0 vs cN+). Pathologic response read by blinded independent central review.
Rectal adenocarcinoma with lower edge ≤10 cm from the anal verge, cT3-4 N0/+ M0, MSS/pMMR, age 18-75, ECOG PS 0-1. No positive lateral lymph node permitted, which excludes the population where lateral nodal management is itself contested.
Both arms received 5Gy x 5 days. The experimental arm's modification was target volume only: radiation to the tumor bed without tumor-draining lymph nodes, against conventional short-course fields in the control. Dose and fractionation were held constant, so the field is the only RT variable.
Experimental: tislelizumab 200 mg IV d1 plus oxaliplatin 130 mg/m² IV d1 and capecitabine 1000 mg/m² PO d1-14. Control: the same CAPOX backbone without tislelizumab. Both followed by TME, then adjuvant therapy and follow-up.
Primary: pCR rate in the ITT population. Secondary: MPR rate, TRG, organ preservation rate, EFS, OS and AEs. Only pCR and MPR are reported in the source; the time-to-event secondaries are not.
The presentation states the experimental approach reduced the incidence of severe gastrointestinal adverse events, consistent with a smaller irradiated volume, but no grade-specific rates are reported in source.
The control arm's 28.6% pCR sits above what short-course RT with consolidation chemotherapy has historically produced in pMMR disease, so the comparator is not obviously weak. The experimental result approaches the response depth usually reserved for dMMR/MSI-H disease, where checkpoint blockade already produces high complete-response rates; extending that to MSS is the claim being made.
Nodal recurrence is the outcome that decides whether sparing the tumor-draining nodes is safe, and no recurrence, EFS or OS data appear in the source. A pCR advantage at TME cannot answer it, and the cN+ stratum is where a nodal-omission failure would show first.
The trial's mechanistic premise, that irradiating draining nodes depletes the lymphocyte reservoir a PD-1 agent needs, is testable but not tested here: the field change and the checkpoint inhibitor were introduced together. A three-arm design (node-sparing RT + CAPOX, conventional RT + CAPOX + tislelizumab) would be needed to separate them.
CONSORT flow
Randomised phase 3, 1° EP met by central review, but confounds nodal-target omission with PD-1 addition and reports no recurrence or survival data.
- Nodal recurrence risk after sparing tumor-draining lymph nodes recruiting Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer Phase 2n=76 · primary completion 2029-06 · nodal-sparing vs standard SCRT TNT in pMMR/MSSrecruiting Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) Phase 2/3n=430 · primary completion 2030-12 · randomised node-sparing vs conventional field, n=430
- Whether tislelizumab or field reduction drives the pCR gain recruiting Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer Phase 2n=186 · primary completion 2024-03 · CRT ± tislelizumab, fixed field: isolates the PD-1 armnot yet Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study Phase 3n=154 · primary completion 2027-12 · phase 3 CRT+chemo ± tislelizumab, ultra-low pMMR/MSS
- Organ preservation and EFS with node-sparing short-course RT recruiting Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer Phase 2n=32 · primary completion 2024-08 · node-sparing SCRT + CAPOX/tisle, organ preservation 2° EP
📚 Sources · 🐦 1 tweet
One of most interesting rectal ca studies at #ASCO26
— Dr. Nina Niu Sanford (@NiuSanford) June 2, 2026
P3 RCT in pMMR LARC: Node-sparing short-course RT + CAPOX + tislelizumab doubled pCR v conventional SCRT + CAPOX (61 v 29%)
Hypothesis = sparing elective node RT preserves antitumor immunity & improves PD1 response @OncoAlert pic.twitter.com/6xvA6ne0mg
The longer read
The number that will travel from this abstract is 61% versus 28.6% pCR, and it deserves attention less for its size than for what the experimental arm changed. Two things moved at once. The radiation field shrank to the tumor bed, sparing the tumor-draining lymph nodes, and tislelizumab was added to the CAPOX backbone. Dose and fractionation were identical at 5Gy x 5d. So the trial cannot tell a reader whether the gain came from the checkpoint inhibitor, from the field reduction, or from an interaction between them, which is precisely the hypothesis the investigators advance. That ambiguity is the central methodological fact and it should temper how much of the effect anyone attributes to nodal sparing.
The mechanistic argument is coherent. Draining lymph nodes are where naive T cells encounter tumor antigen, and irradiating them plausibly removes the reservoir a PD-1 agent depends on. Preclinical work has pointed this direction for several years. But a coherent mechanism plus a positive combined arm is a weaker form of evidence than it feels like, because adding PD-1 blockade to chemotherapy in the neoadjuvant rectal setting has its own precedent for raising response depth. The simplest explanation for a doubled pCR in a pMMR population is the drug, and the field change would then be permissive rather than causal. A three-arm design separating conventional RT plus tislelizumab from node-sparing RT plus tislelizumab is what would settle it, and nothing in this trial substitutes for that.
What makes the result harder to dismiss is that the control arm is not a straw man. Short-course radiotherapy followed by consolidation CAPOX is a defensible standard, and 28.6% pCR is in the range that approach has produced elsewhere rather than below it. The comparison is therefore against real practice, and the delta is large enough that it is unlikely to be noise at n=77 per arm with a centrally read pathologic endpoint. Blinded independent central review matters here more than usual: in an open-label trial, pathologic complete response is one of the few endpoints where blinding at the assessment step genuinely neutralizes the design's main bias.
The unresolved question is the one that decides whether any of this changes a radiation plan. Elective nodal coverage exists to sterilize microscopic mesorectal and pelvic nodal disease, and its payoff is measured in locoregional recurrence over years, not in response at surgery. This population includes cN+ patients, stratified as such, and the source reports no recurrence, EFS, or OS data at all. A higher pCR rate in an arm whose nodes were never irradiated is compatible with excellent long-term nodal control and equally compatible with a delayed nodal relapse signal that emerges at three years. Both arms proceeded to TME, which removes the mesorectum and provides some protection against that failure mode, but does not cover the lateral or extramesorectal stations that elective fields reach.
For now this is a hypothesis worth a confirmatory trial rather than a reason to redraw a target volume. The reported reduction in severe gastrointestinal toxicity is the expected consequence of a smaller field and is the least surprising finding in the abstract. The response result is genuinely interesting. Whether it survives contact with locoregional recurrence data is the only thing that will determine if node-sparing becomes a real question in rectal radiotherapy or stays a mechanistic curiosity.